Pharmaceuticals for Inflammatory Bowel Disease (IBD)
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 June 2025 | Viewed by 60
Special Issue Editor
Interests: pharmaceutical chemistry; drug discovery; medicinal plants; inflammatory bowel disease; cancer; diabetes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammatory bowel disease (IBD) is a chronic and debilitating inflammation of the gastrointestinal tract. It comprises Crohn’s and Ulcerative Colitis. IBD affects industrialized countries. The causes of IBD are not well established. However, its pathogenesis has been linked to genetics, microbiome, environment, and lifestyle. The clinical symptoms include loss of appetite, weight loss, severe abdominal cramps, constant diarrhea, and rectal bleeding. There is no cure for IBD, and the existing treatments, which are used for the induction and maintenance of IBD remission, are expensive and come with unwanted side effects. As a result, this comes with huge social, economic, and health burdens for people and countries. In their desperate searches for a cure, patients with IBD have been using herbal medicines, helminth therapy, and fecal microbiota transplant with limited success. There is a need for novel and effective treatments. Treatments can be developed from natural products or synthetically in laboratories. This Special Issue is dedicated to bringing in treatment perspectives from IBD clinicians, researchers, and patients.
Dr. Phurpa Wangchuk
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease
- IBD symptoms
- IBD pathogenesis
- IBD treatments
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
